The Importance of the Immune System

The immune system is the body’s primary defense against viruses, bacteria, and parasites that cause disease in millions of people every year. In addition, the immune system helps the body resist the development of cancer and other illnesses.

When the immune system is operating properly, it provides powerful protection against a variety of diseases. It can, however, be a double-edged sword. When it is underactive, it can leave the body vulnerable to infection. And when it is overly active, it can damage normal organs and tissues, causing illnesses such as allergy, asthma, inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, rheumatoid arthritis, type 1 diabetes, and other autoimmune diseases.

Research scientists and clinicians are working to harness this powerful defense system to protect people and animals against naturally occurring infectious diseases, potential bioterrorism agents, cancer, and autoimmune diseases. Basic research focused on understanding and controlling the immune system is essential to discovering better ways to prevent and treat disease.
Major Immunological Advances in Preventing and Treating Infectious Diseases

Vaccines

Vaccination is a critical public health strategy that helps train the immune system to protect against an encounter with harmful bacteria or viruses that can cause life-threatening illnesses. Vaccines have led to the eradication of smallpox worldwide, the elimination of polio from the United States, and the control of many childhood diseases (including measles, mumps, and rubella) that once routinely sickened or killed infants and children. Use of vaccines against high-risk forms of human papillomavirus (HPV), which cause about 91% of cervical and anal cancers, have reduced the U.S. incidence of HPV in female teenagers by more than 80%. For older adults, vaccines can prevent or reduce the severity of shingles and pneumonia.

Vaccines against COVID-19 are saving millions of lives and preventing severe disease worldwide. Other vaccines are being developed to help protect against infectious diseases including malaria, dengue, and Ebola. Research is also underway to develop a universal influenza vaccine, vaccines to protect against respiratory syncytial virus (RSV), and a more efficacious vaccine against tuberculosis.

COVID-19

Scientists responded rapidly to the COVID-19 pandemic, caused by the virus SARS-CoV-2, by developing several vaccines in record time that are highly effective at preventing severe disease, hospitalization, and death. Scientists have also developed novel therapies, such as monoclonal antibodies and antiviral drugs, that can significantly reduce COVID-19 severity.

Mutations in the original virus have resulted in variants (e.g., Delta and Omicron) that spread more easily and/or can evade vaccines and therapies. Immunological research helped lead to Food and Drug Administration (FDA) approval of a bivalent vaccine, targeting both the original strain and the Omicron variant, which provides even greater protection than the original vaccines. Scientists are also working to develop a pan-coronavirus vaccine, which could protect against current and future variants. Other vaccine candidates, including one inhaled nasally, aim to block infection and/or extend the durability of the immune response.

HIV and AIDS

Left untreated, the highly infectious HIV virus, which attacks and disables a critical part of the immune system, leads to the deadly disease AIDS. Decades ago, a person with HIV/AIDS was unlikely to live longer than a few years. Today, a person living with HIV who receives antiretroviral therapy can expect to live a nearly normal lifespan with little risk of sexually transmitting the virus. Because current therapies only suppress the virus, NIH is supporting research on new strategies to prevent infection, reduce transmission, and eradicate the virus in persons living with HIV. For example, NIH scientists are currently testing a promising messenger RNA (mRNA) vaccine against HIV and have successfully induced remission (no detectable virus) through a stem cell transplant in a third person.

Influenza

Influenza (flu) is a respiratory virus that can cause serious illness, particularly in the elderly, leading to the hospitalization and/or death of hundreds of thousands of people in the U.S. each year. Influenza mutates rapidly, leading to multiple strains that may circulate each year. Newly emerging strains, like the 2009 H1N1 “swine flu,” can be especially dangerous; because of a lack of prior immunity in the population, such strains can be more contagious and deadly, with the potential to cause a pandemic. NIH-funded influenza research has driven several recent advances in vaccines, including a phase 1 study testing a new way to administer flu vaccines, and the first phase 1 clinical trial of a vaccine designed to provide universal protection against many different strains of influenza.

Malaria and Tuberculosis

Malaria and tuberculosis (TB) are leading global causes of death. An estimated 13 million Americans are infected with TB, and malaria remains a significant threat to American service members stationed overseas. NIH-funded research has led to several recent breakthroughs in the prevention of these diseases, including the distribution of the first licensed and World Health Organization-recommended malaria vaccine; clinical trials which demonstrate protection against malaria by a monoclonal antibody; and a new vaccination method (intravenous) that provides the most effective protection ever achieved against TB.

(continued)
Immunological Advances that Have Changed the Course of Cancer, Autoimmune Diseases, and More

**Cancer**

Cancer research continues to focus on understanding the complex interactions between tumor cells and healthy (including immune) cells in the tumor microenvironment. Scientists are also utilizing vast, comprehensive genetic and metabolic data to advance our understanding, diagnosis, and treatment of cancer.

Remarkable advancements have been made in the field of cancer immunotherapy, in which the patient’s own immune system is stimulated or suppressed to fight cancer, including CAR-T cell therapy (engineered immune cells that can identify and eliminate tumor cells); cancer vaccine research (including testing mRNA vaccines); and better understanding the microbiome’s influence on tumor growth. Immunotherapies and targeted therapies (drugs that inhibit cancer cell growth) have resulted in long-term remission for some cancer patients, including those who previously had limited options for successful treatment.

**Autoimmunity**

Autoimmune diseases are chronic illnesses in which a person’s own immune system attacks their body. There are more than 80 autoimmune diseases, afflicting up to 23.5 million Americans, which can affect any region of the body, including the gastrointestinal system (e.g., inflammatory bowel disease), the musculoskeletal system (e.g., rheumatoid arthritis), the brain (e.g., multiple sclerosis), the metabolic systems (e.g., type 1 diabetes), and multiple organ systems at once (e.g., systemic lupus erythematosus).

NIH-supported research has identified the immune cells and molecules that cause some of these diseases, enabling the development of needed therapeutics. These medicines, including immunotherapies (treatments that utilize parts of a patient’s immune system to fight disease), have been used with some success to treat rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease by regulating the immune response. However, more research is needed to better understand and treat these and other autoimmune diseases, including allergies and asthma.

(continued)
Economic Benefits of Biomedical Research

High Quality Jobs
Discoveries funded by the National Institutes of Health (NIH) make possible a vibrant and innovative U.S. life sciences industry which directly supports about 1.87 million high-quality scientific jobs with an average annual salary of $107,000.¹ These jobs are the economic engine for many communities around the nation.

In fiscal year (FY) 2021, NIH funding directly or indirectly supported more than 552,000² jobs at approximately 2,500 academic and research institutions across the U.S.³

Return on Investment
Every $1 of NIH funding produces $2.60 in economic output.⁴ Investment in NIH contributed more than $94.18 billion to the U.S. Gross Domestic Product in 2021.⁵

Impact on Industry
The basic discoveries of NIH-supported researchers are crucial to industry success in developing new products, including vaccines and other drugs, to prevent and treat disease. According to a bipartisan Senate Health, Education, Labor, and Pensions Committee report, “early stage research is high-risk—prone to high failure rates—making it less attractive to industry investment or undertaking, but these basic research findings form the foundation of the biomedical research continuum. NIH plays a vital role in its support of basic research. …”⁶

A report published in the Proceedings of the National Academies of Sciences found that NIH-funded research contributed to all 210 of the new drugs approved by the Food and Drug Administration from 2010-2016.⁷ This may be the strongest evidence to date that basic research funded by NIH is an essential and irreplaceable part of the biomedical research pipeline that leads to lifesaving and life-changing new drugs.

Global Competitiveness
Despite recent increases in federal biomedical research funding, the growth rate for U.S. research and development (R&D) spending remains relatively low, especially in comparison with some of our economic competitors. For example, from 2010-2019, China’s R&D spending increased by 10.6% annually, compared to an average annual increase of 5.4% in the U.S.⁸ Due to China’s strong and consistent investment in R&D, it has already surpassed the U.S. in key metrics, including the number of patents granted and the total number of scientific publications each year.⁹

Increased investment in U.S. R&D will bolster innovation, strengthen our economy, and give the U.S. a competitive edge, enabling the U.S. to maintain its preeminence in biomedical research.

² https://unitedformedicalresearch.org/annual-economic-report/
³ https://www.nih.gov/about-nih/what-we-do/budget
⁴ See endnote 2
⁵ See endnote 2
⁶ http://www.help.senate.gov/imo/media/Innovation_for_Healthier_Americans.pdf
⁷ https://www.pnas.org/content/115/10/2329

© 2023 The American Association of Immunologists, Inc.
NIH’s mission is “to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.”

NIH is comprised of 27 Institutes and Centers, most of which conduct research on diseases or body systems. While about 10% of its budget supports the research of nearly 6,000 scientists in its own laboratories, more than 84% of its budget funds the work of about 300,000 extramural scientists at 2,500 universities, medical schools, and other research institutions in every state across the nation. Importantly, this includes support for the training of more than 35,000 graduate students and nearly 29,000 postdoctoral fellows in FY 2022.

A History of Success

NIH-supported researchers have received almost 170 Nobel Prizes and more than 210 Lasker Awards.

NIH-funded biomedical research has helped to dramatically lengthen—and improve—the lives of millions of Americans. In 2019, then-NIH Director Francis Collins, M.D., Ph.D., explained that “[l]ife expectancy for a baby born in the U.S. has risen from 47 years in 1900 to more than 78 years today. Among the advances that have helped to make this possible are a 70% decline in the U.S. death rate from cardiovascular disease over the past 50 years, and a drop of more than 1% annually in the cancer death rate over the past couple of decades.”

Although life expectancy has declined over the last several years due to several public health crises, including the COVID-19 pandemic and the opioid epidemic, NIH-funded research has supported the development of new vaccines and treatments that could help reverse this trend.

1 http://www.nih.gov/about-nih
3 https://www.nih.gov/about-nih/what-we-do/impact-nih-research/revolutionizing-science/scientific-breakthroughs
The American Association of Immunologists (AAI) recommends an appropriation of at least $51 billion for the base budget of the National Institutes of Health (NIH) for fiscal year (FY) 2024 to enable NIH to invest robustly in the next generation of biomedical researchers while providing ample support for established investigators who lead laboratories, train and teach aspiring scientists and medical students, and bring the latest scientific discoveries to patients’ bedsides. Largely because of NIH funding, researchers across all career stages have made remarkable scientific discoveries, with many more on the horizon.

AAI thanks Congress for its strong bipartisan support for NIH, which has enabled the agency’s budget to grow significantly over the past eight years. However, this investment in NIH follows many years of insufficient funding; it was only recently that the NIH budget, after adjusting for inflation, was restored to its FY 2003 level. Robust, sustained, and predictable funding increases are needed to ensure adequate investment in health priorities including cancer, Alzheimer’s disease, autoimmune diseases, and emerging infectious diseases like COVID-19, and in a talented, diverse biomedical research workforce.

For more details on AAI funding priorities, please visit: http://www.aai.org/Public-Affairs/Advocacy-Center

Advanced Research Projects Agency for Health

AAI supports the recently-created Advanced Research Projects Agency for Health (ARPA-H), which will fund high-risk, high-reward research projects with the potential to lead to transformative biomedical and health breakthroughs. Though part of NIH, ARPA-H is designed to operate independently with its own mission and culture, a higher tolerance for risk, and significantly different processes for applying for funding and reviewing research proposals.

AAI believes that ARPA-H, which has received $2.5 billion in appropriations to date, needs substantial, continued investment to flourish. It is vital, however, that any funding provided to ARPA-H supplement, and not supplant, the NIH base budget. Funding ARPA-H at the expense of the NIH base budget could do great harm to the core functions of NIH, including its investigator-initiated basic research portfolio.
About AAI

AAI is the nation’s largest professional association for immunologists. Since 1913, AAI has been dedicated to advancing the work of our members — research scientists and physicians who are the world’s leading experts on the biology of the immune system and whose discoveries lead to the prevention, treatment, and cure of many life-threatening and debilitating diseases.

AAI represents immunologists from every state and around the globe. Our members include principal investigators, staff scientists, postdoctoral fellows, graduate students, lab managers, and other professionals who support our mission: to advance knowledge within immunology and related disciplines, foster the interchange of ideas and information among scientists, and promote a better understanding of the field of immunology.

AAI is the owner and publisher of The Journal of Immunology (The JI), the most highly-cited journal in the field of immunology. The JI has published novel, peer-reviewed findings in all areas of experimental immunology since 1916. AAI also owns and publishes ImmunoHorizons, an open access, fully peer-reviewed journal committed to advancing the knowledge of immunology by publishing articles that cover all areas of basic and clinical immunology.

AAI is a founding member of the Federation of American Societies for Experimental Biology (FASEB), which is comprised of more than 25 professional societies and 115,000 researchers and is the largest coalition of biomedical research associations in the United States.

The American Association of Immunologists
1451 Rockville Pike, Suite 650
Rockville, MD 20852
(301) 634-7178
infoaai@aai.org
www.aai.org

Follow us on Facebook and Twitter!

© 2023 The American Association of Immunologists, Inc.